PMID- 31069192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2278-330X (Print)
IS  - 2278-4306 (Electronic)
IS  - 2278-330X (Linking)
VI  - 8
IP  - 2
DP  - 2019 Apr-Jun
TI  - Effectiveness and tolerability of nimotuzumab in unresectable, locally 
      advanced/metastatic esophageal cancer: Indian hospital-based retrospective 
      evidence.
PG  - 112-115
LID - 10.4103/sajc.sajc_89_18 [doi]
AB  - CONTEXT: Epidermal growth factor receptor (EGFR) is overly expressed in 
      esophageal squamous cell carcinoma (ESCC) and is important prognostic and 
      predictive biomarker. Nimotuzumab is a humanized anti-EGFR monoclonal antibody 
      and has documented promising clinical outcomes and survival rates in various 
      solid tumors with high EGFR expression. AIMS: Attempt to fill gap on paucity of 
      data in India on the efficacy of Nimotuzumab in the treatment of locally 
      advanced/metastatic ESCC. SETTINGS AND DESIGN: Hospital records of 15 patients 
      with unresectable, locally advanced/metastatic esophageal cancers, histologically 
      confirmed squamous cell carcinoma being treated with Nimotuzumab along with 
      standard treatments from October 2006 to November 2016 were retrospectively 
      analyzed. SUBJECTS AND METHODS: The tumor response rate and overall survival (OS) 
      were analyzed. All patients were assessed for toxicity and adverse events (AEs) 
      as per Common Terminology Criteria for Adverse Events (CTCAE) v4. RESULTS: 
      Majority had lower thoracic esophageal cancer. Tumor response rate observed was 
      as follows 33% had a complete response, 67% had a partial response, and objective 
      response rate was 100%. Survival rate at 1-, 3-, and 5-year was 58.33%, 29.17%, 
      and 29.17%, respectively. Median OS was 26.8 months (95% confidence interval, 
      2.63-not reached). No Grade III or Grade IV AEs were observed. No added toxicity 
      was observed due to nimotuzumab. CONCLUSIONS: Nimotuzumab combined with standard 
      treatment in locally advanced/metastatic ESCC improved the survival rate and 
      achieved a better tumor response rate without accumulation of toxicity and was 
      well tolerated.
FAU - Subramanian, Sundaram
AU  - Subramanian S
AD  - V. S Hospital and Cancer Center, Chennai, Tamil Nadu, India.
FAU - Sridharan, Nithya
AU  - Sridharan N
AD  - V. S Hospital and Cancer Center, Chennai, Tamil Nadu, India.
FAU - Balasundaram, V
AU  - Balasundaram V
AD  - V. S Hospital and Cancer Center, Chennai, Tamil Nadu, India.
FAU - Chaudhari, Sameer
AU  - Chaudhari S
AD  - Medical advisor, Biocon Ltd, Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - South Asian J Cancer
JT  - South Asian journal of cancer
JID - 101618774
PMC - PMC6498719
OTO - NOTNLM
OT  - Advanced
OT  - antibodies
OT  - carcinoma
OT  - esophageal neoplasms
OT  - inoperable
OT  - metastatic
OT  - monoclonal
OT  - nimotuzumab
OT  - overall survival
OT  - squamous cell
OT  - tumor response
COIS- There are no conflicts of interest.
EDAT- 2019/05/10 06:00
MHDA- 2019/05/10 06:01
PMCR- 2019/04/01
CRDT- 2019/05/10 06:00
PHST- 2019/05/10 06:00 [entrez]
PHST- 2019/05/10 06:00 [pubmed]
PHST- 2019/05/10 06:01 [medline]
PHST- 2019/04/01 00:00 [pmc-release]
AID - SAJC-8-112 [pii]
AID - 10.4103/sajc.sajc_89_18 [doi]
PST - ppublish
SO  - South Asian J Cancer. 2019 Apr-Jun;8(2):112-115. doi: 10.4103/sajc.sajc_89_18.